Zacks Investment Research
17 Jul 2026, 14:46 UTC · 1h ago
Is Humana (HUM) Stock Outpacing Its Medical Peers This Year?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
17 Jul 2026, 14:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Humana (HUM) currently holds a Zacks Rank of #1 (Strong Buy). — A top-tier analyst rank often triggers increased buying pressure from retail and systematic investors.
+0.40The Zacks Consensus Estimate for Humana's full-year earnings has increased by 5.3% over the last 90 days. — Positive earnings revisions are a strong fundamental signal for future price appreciation.
+0.30Envoy Medical, Inc. (COCH) currently holds a Zacks Rank of #2 (Buy). — A positive rating is bullish for the specific ticker, though less impactful than a #1 rank.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company has a Zacks Rank #1 (Strong Buy), has outperformed its sector by over 50% year-to-date, and has seen an increase in earnings estimates.
The company has a Zacks Rank #2 (Buy), has returned 15% year-to-date, and has seen a rise in consensus EPS estimates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.